Skip to content

UltiMaker and Bioactivx to co-develop a scalable, on-demand medical printing solution for regenerative wound care

Share this article

LinkedInFacebookXWhatsAppE-mail

3D ADEPT · AUDIO

Listen to this article

3 min

Narrated using a synthetic voice.

UltiMaker and Bioactivx representatives presenting signed documents.
From left to right: UltiMaker CEO, Michiel Alting von Geusau, Member of Parliament and Guest of Honor Ms Tin Pei Ling, and BioactivX CEO, Dr Peili Teo, at the MOU signing.

3D printing company UltiMaker signed a Memorandum of Understanding (MOU) with Bioactivx, a Singapore-based MedTech startup. Together, they will co-develop a scalable, on-demand medical printing solution for regenerative wound care.

The announcement coincides with two major milestones for Bioactivx. The first is the opening of its medical-grade filament production and cleanroom print farm facility. The second, according to the announcement, is HSA approval for its flagship product Bioactiv® Matrix. Bioactivx manufactures it using UltiMaker’s 3D printing platform.

Singapore’s HSA is classified as WHO maturity level 4 for medical device regulations, indicating extremely high standards for medical device approvals. Regulatory submissions for the Bioactiv® Matrix in key countries/regions such as USA, EU, Australia and the rest of ASEAN are ongoing.

Bioactiv® Matrix

Bioactivx’s flagship product, Bioactiv® Matrix, is described by the company as a synthetic, animal-free regenerative medical solution designed to accelerate wound closure and promote scar-free healing.

To bring it to market at scale, Bioactivx built an end-to-end digital manufacturing process. It compounds a proprietary active-ingredient filament in-house. It then mass-produces the final product on a fleet of UltiMaker 3D printers within a certified cleanroom.

“We chose UltiMaker because of its reliability, ease of use, and open architecture,” said Dr. Teo Peili, CEO of Bioactivx. “That openness was essential – it let us develop and fine-tune our own proprietary print process rather than working around the limitations of a closed system.”

Under the newly signed MOU, UltiMaker and Bioactivx will jointly develop a scalable, deployable printing solution aimed at bringing wound care production closer to the point of need.

The two companies aim to enable faster access to treatment within the critical “golden period” following injury. To do so, they seek to reduce dependency on traditional cold-chain logistics and centralized manufacturing.

THE 3D ADEPT WEEKLY NEWSLETTER

The industry moves fast. Stay ahead.

Every week, the latest additive manufacturing news, in-depth features and real-world applications, straight to your inbox. Plus, be the first to know when a new issue of 3D ADEPT Mag is out.

Free · One email a week · Unsubscribe anytime

Clicking loads our email provider’s sign-up form, including its analytics and Google’s anti-bot protection. You’re only subscribed if you complete the sign-up. Read our privacy policy.

Open the form in a new tab ↗

Share this article

LinkedInFacebookXWhatsAppE-mail

The weekly newsletter

Essential AM knowledge, delivered weekly.

News, in-depth features and industry perspectives, in your inbox.

Receive the newsletter